Erasca, Inc. Common Stock
Symbol: ERAS (NASDAQ)
1.66
▲ (5.41%) 0.085
Company Description:
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Key Stats
- Today's Open: $1.58
- Today's High: $1.655
- Today's Low: $1.555
- Today's Volume: 456.87K
- Yesterday Close: $1.57
- Yesterday High: $1.63
- Yesterday Low: $1.55
- Yesterday Volume: 812.06K
- Last Min Volume: 25
- Last Min High: $1.655
- Last Min Low: $1.655
- Last Min VWAP: $1.655
Company Profile
- Name: Erasca, Inc. Common Stock
- Website: https://www.erasca.com
- Listed Date: 2021-07-16
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001761918
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $445.36M
- Round Lot: 100
- Outstanding Shares: 283.67M
- Asset Type: CS
RECENT FILINGS FOR ERAS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-15 | 144 | View |
| 2025-08-14 | SCHEDULE 13G | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-13 | SCHEDULE 13G | View |
| 2025-08-12 | S-3 | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-07-15 | 144 | View |
| 2025-06-26 | 8-K | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-16 | 144 | View |
| 2025-06-03 | 4 | View |
| 2025-05-15 | 144 | View |
Latest News on ERAS